<DOC>
	<DOCNO>NCT00173875</DOCNO>
	<brief_summary>The purpose study ass overall response rate Iressa first-line treatment chemonaive patient inoperable Non-Small Cell Lung Cancer ( NSCLC )</brief_summary>
	<brief_title>Iressa First-Line Treatment Chemonaive Patients With Inoperable Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>The epidermal growth factor receptor ( EGFR ) promise target anticancer therapy express highly express variety tumor , include NSCLC.Furthermore , high level EGFR expression associate poor prognosis lung cancer patient several study . EGFR-targeted cancer therapy currently develop ; strategy include inhibition intracellular tyrosine kinase domain receptor small molecule gefitinib ( Iressa [ ZD1839 ] ; AstraZeneca , Wilmington , DE ) . Iressa orally active , selective EGFR tyrosine kinase inhibitor block signal transduction pathway implicate proliferation survival cancer cell .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically cytologically confirm stage IIIB/IV NSCLC No immediate need palliative radiotherapy No prior chemotherapy age &gt; 20 Y/O ECOG PS : 0 2 ANC &gt; 2000 PLT &gt; 100k Hb &gt; 10 total bilirubin &lt; 2.0 mg/dL serum creatinine &lt; 2 mg/dl SGPT SGOT &lt; 2.5 ×ULN , alkaline phosphatase &lt; 5 ×ULN life expectancy &gt; 6mos . If patient brain metastasis receive radiotherapy , disease must stable 6 week last dose radiotherapy 2nd malignancy Unable swallow tablet Patients ( M/F ) reproductive potential implementing adequate contraceptive measurement Pregnant lactate patient Participation clinical trial within 30 day study entry Major systemic disease investigator 's opinion might confound clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
	<keyword>EGFR Non-small cell lung cancer</keyword>
</DOC>